, Facteurs de risque -Cancer du sein | Institut National Du Cancer, p.13

, Le cancer du sein -Les cancers les plus fréquents | Institut National Du Cancer, p.13, 2018.

, Disponible sur, p.13, 2018.

D. Sur,

X. Sastre-garau, M. Jouve, B. Asselain, A. Vincent-salomon, P. Beuzeboc et al., Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns, Cancer. 1 janv, vol.77, issue.1, pp.113-133, 1996.

C. I. Li, N. S. Weiss, J. L. Stanford, and J. R. Daling, Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women, Cancer. 1 juin, vol.88, issue.11, pp.2570-2577, 2000.

C. I. Li, B. O. Anderson, P. Porter, S. K. Holt, J. R. Daling et al., Changing incidence rate of invasive lobular breast carcinoma among older women, Cancer. 1 juin, vol.88, issue.11, pp.2561-2570, 2000.

P. Chand, A. Garg, V. Singla, and R. N. , Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use, Niger J Surg Off Publ Niger Surg Res Soc, vol.24, issue.2, pp.100-106, 2018.

C. W. Elston and I. O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology. nov, vol.19, issue.5, pp.403-413, 1991.

L. Doussal, V. Tubiana-hulin, M. Friedman, S. Hacene, K. Spyratos et al., Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR)

, An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer, vol.64, pp.1914-1935, 1989.

, Estrogen receptors: how do they signal and what are their targets. -PubMed -NCBI, 2018.

D. Sur,

M. Hammond, D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty et al.,

, College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version), Arch Pathol Lab Med. juill, vol.134, issue.7, pp.48-72, 2010.

C. Bansal, A. Sharma, M. Pujani, M. Pujani, K. L. Sharma et al., Correlation of Hormone Receptor and Human Epidermal Growth Factor Receptor-2/neu Expression in Breast Cancer with Various Clinicopathologic Factors, Indian J Med Paediatr Oncol Off J Indian Soc Med Paediatr Oncol, vol.38, issue.4, pp.483-492, 2017.

. Ebctcg), C. Davies, J. Godwin, R. Gray, M. Clarke et al., Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet Lond Engl, vol.27, issue.9793, pp.771-84, 2011.

«. Référentiel and . Sein, , 2018.

F. Disponible-sur-;-dehdashti, R. Laforest, F. Gao, R. L. Aft, C. S. Dence et al., Assessment of Progesterone Receptors in Breast Carcinoma by PET with 21-18F-Fluoro-16?,17?-[(R)-(1?-?furylmethylidene) Dioxy]-19-Norpregn-4-Ene-3,20-Dione, J Nucl Med Off Publ Soc Nucl Med. mars, vol.53, issue.3, pp.363-70, 2012.

D. Sur,

L. Arnould, Y. Denoux, G. Macgrogan, F. Penault-llorca, M. Fiche et al., Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer, Br J Cancer. 19 mai, vol.88, issue.10, pp.1587-91, 2003.

E. A. Perez, E. H. Romond, V. J. Suman, J. Jeong, G. Sledge et al., Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.33, pp.3744-52, 2014.

M. Faheem, H. Mahmood, M. Khurram, U. Qasim, and J. Irfan, Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan, Ecancermedicalscience, vol.6, p.283, 2012.

P. Taneja, D. Maglic, F. Kai, S. Zhu, R. D. Kendig et al., Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance, Clin Med Insights Oncol. 20 avr, vol.4, pp.15-34, 2010.

D. E. Carvajal-hausdorf, K. A. Schalper, L. Pusztai, A. Psyrri, K. T. Kalogeras et al., Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer, J Natl Cancer Inst. août, issue.8, p.107, 2015.

J. Gerdes, H. Lemke, H. Baisch, H. H. Wacker, U. Schwab et al., Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki

, Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology (Phila), J Immunol Baltim Md, vol.133, issue.4, pp.166-71, 1950.

K. Kontzoglou, V. Palla, G. Karaolanis, I. Karaiskos, I. Alexiou et al., Correlation between Ki67 and breast cancer prognosis, Oncology, vol.84, issue.4, pp.219-244, 2013.

I. F. Faneyte, J. G. Schrama, J. L. Peterse, P. L. Remijnse, S. Rodenhuis et al., Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome, Br J Cancer. 10 févr, vol.88, issue.3, pp.406-418, 2003.

M. J. Ellis, V. J. Suman, J. Hoog, R. Goncalves, S. Sanati et al., Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance), J Clin Oncol. 1 avr, vol.35, issue.10, pp.1061-1070, 2017.

N. Pathmanathan and R. L. Balleine, Ki67 and proliferation in breast cancer, J Clin Pathol. juin, vol.66, issue.6, pp.512-518, 2013.

E. Luporsi, F. André, F. Spyratos, P. Martin, J. Jacquemier et al., Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res Treat. avr, vol.132, issue.3, pp.895-915, 2012.

M. Dowsett, T. O. Nielsen, A. 'hern, R. Bartlett, J. Coombes et al., Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group, JNCI J Natl Cancer Inst, vol.103, issue.22, pp.1656-64, 2011.

R. Tashima, R. Nishimura, T. Osako, Y. Nishiyama, Y. Okumura et al., Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study, Disponible sur, vol.10, pp.747-52, 2000.

, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, 2018.

A. Prat, E. Pineda, B. Adamo, P. Galván, A. Fernández et al., Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast, vol.24, pp.26-35, 2015.

M. Cheang, S. K. Chia, D. Voduc, D. Gao, S. Leung et al., , p.2

, prognosis of patients with luminal B breast cancer, J Natl Cancer Inst. 20 mai, vol.101, issue.10, pp.736-50, 2009.

A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thürlimann et al., Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St

, Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2011.

, Ann Oncol Off J Eur Soc Med Oncol. août, vol.22, issue.8, pp.1736-1783, 2011.

J. M. Cejalvo, T. Pascual, A. Fernández-martínez, F. Brasó-maristany, R. R. Gomis et al., Clinical implications of the non-luminal intrinsic subtypes in hormone receptorpositive breast cancer, Cancer Treat Rev. juin, vol.67, pp.63-70, 2018.

A. S. Coates, E. P. Winer, A. Goldhirsch, R. D. Gelber, M. Gnant et al., Tailoring therapies--improving the management of early breast cancer, St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, vol.26, pp.1533-1579, 2015.

Z. Inic, M. Zegarac, M. Inic, I. Markovic, Z. Kozomara et al., Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information, Clin Med Insights Oncol, vol.8, pp.107-118, 2014.

M. A. Lavasani and F. Moinfar, Molecular classification of breast carcinomas with particular emphasis on « basal-like » carcinoma: a critical review, J Biophotonics. avr, vol.5, issue.4, pp.345-66, 2012.

Z. Li, P. Hu, J. Tu, and N. Yu, Luminal B breast cancer: patterns of recurrence and clinical outcome, Oncotarget. 17 août, vol.7, issue.40, pp.65024-65057, 2016.

J. M. Baena-cañada, R. Daffós, P. , D. Díaz, V. et al.,

, Rev Calid Asist Organo Soc Espanola Calid Asist. août, vol.25, issue.4, pp.228-259, 2010.

A. E. Giuliano, J. L. Connolly, S. B. Edge, E. A. Mittendorf, H. S. Rugo et al., Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, vol.08, issue.4, pp.290-303, 2017.

S. Tian, P. Roepman, L. J. Van't-veer, R. Bernards, F. De-snoo et al., Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer, Biomark Insights, vol.28, pp.129-167, 2010.

S. Paik, S. Shak, G. Tang, C. Kim, J. Baker et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, vol.351, issue.27, pp.2817-2843, 2004.

J. A. Sparano, R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain et al.,

, Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer, N Engl J Med. 12 juill, vol.379, issue.2, pp.111-132, 2018.

J. A. Sparano, R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain et al.,

, Prospective Validation of a 21-Gene Expression Assay in Breast Cancer, N Engl J Med, vol.373, issue.21, pp.2005-2019, 2015.

, Haute Autorité de Santé -Utilité clinique des signatures génomiques dans le cancer du sein de stade précoce -Rapport d'évaluation

F. Disponible-sur-;-fitzal, M. Filipits, M. Rudas, R. Greil, O. Dietze et al., The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial, Br J Cancer. 14 avr, vol.112, issue.8, pp.1405-1415, 2015.

M. Polley, S. Leung, L. M. Mcshane, D. Gao, J. C. Hugh et al., An international Ki67 reproducibility study, J Natl Cancer Inst. 18 déc, vol.105, issue.24, pp.1897-906, 2013.

S. Leung, T. O. Nielsen, L. Zabaglo, I. Arun, S. S. Badve et al., Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration, NPJ Breast Cancer, vol.2, p.16014, 2016.

S. Bustreo, S. Osella-abate, P. Cassoni, M. Donadio, M. Airoldi et al., Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up, Breast Cancer Res Treat, vol.157, pp.363-71, 2016.

L. Orlando, G. Viale, E. Bria, E. S. Lutrino, I. Sperduti et al., Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment, Breast Edinb Scotl. déc, vol.30, pp.151-156, 2016.

M. Lee, C. S. Lee, and P. H. Tan, Hormone receptor expression in breast cancer: postanalytical issues, J Clin Pathol. juin, vol.66, issue.6, pp.478-84, 2013.

E. Hadi, H. Abdellaoui-maane, I. Kottwitz, D. El-amrani, M. Bouchoutrouch et al., Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer, Gene. 20 mars, vol.605, pp.114-136, 2017.

B. E. Wasserman, D. E. Carvajal-hausdorf, K. Ho, W. Wong, N. Wu et al., High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence, Lab Investig J Tech Methods Pathol. déc, vol.97, issue.12, pp.1521-1527, 2017.

A. C. Wolff, M. Hammond, K. H. Allison, B. E. Harvey, P. B. Mangu et al.,

, College of American Pathologists Clinical Practice Guideline Focused Update, J Clin Oncol Off J Am Soc Clin Oncol. 30 mai, 2018.

C. Tse and J. Capeau, Quantification des acides nucléiques par PCR quantitative en temps réel, Ann Biol Clin (Paris). 1 mai, vol.61, issue.3, pp.279-93, 2003.

F. Kwiatkowski, M. Girard, K. Hacene, and J. Berlie,

A. M. Gordian-arroyo, D. L. Zynger, and G. H. Tozbikian, Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update, Am J Clin Pathol. 8 avr, vol.87, issue.10, pp.715-736, 2000.

, Les chiffres clés du cancer en France

, Disponible sur: /article/26089_les-chiffres-cles-des-cancers

, Haute Autorité de Santé -Cancer du sein : modalités spécifiques de dépistage pour les femmes à haut risque

W. M. Hanna, J. Rüschoff, M. Bilous, R. A. Coudry, M. Dowsett et al., HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity, Mod Pathol Off J U S Can Acad Pathol Inc. janv, vol.27, issue.1, pp.4-18, 2014.

M. Polley, S. Leung, D. Gao, M. G. Mastropasqua, L. A. Zabaglo et al., An international study to increase concordance in Ki67 scoring, Mod Pathol Off J U S Can Acad Pathol Inc. juin, vol.28, issue.6, pp.778-86, 2015.

D. A. Yardley, P. A. Kaufman, W. Huang, L. Krekow, M. Savin et al., Quantitative measurement of HER2 expression in breast cancers: comparison with « realworld » routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival, Breast Cancer Res BCR. 18 mars, vol.17, p.41, 2015.

C. Denkert, J. Budczies, G. Von-minckwitz, S. Wienert, S. Loibl et al., Strategies for developing Ki67 as a useful biomarker in breast cancer, Breast Edinb Scotl. nov, vol.24, issue.2, pp.67-72, 2015.

M. Laible, K. Schlombs, K. Kaiser, E. Veltrup, S. Herlein et al., Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens, BMC Cancer, vol.07, p.398, 2016.

L. N. Harris, N. Ismaila, L. M. Mcshane, F. Andre, D. E. Collyar et al., Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer, J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.34, issue.10, pp.1134-50, 2016.

H. Sinn, A. Schneeweiss, M. Keller, K. Schlombs, M. Laible et al., Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer, BMC Cancer, vol.13, issue.1, p.124, 2017.

A. E. Rizzardi, A. T. Johnson, R. I. Vogel, S. E. Pambuccian, J. Henriksen et al., Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring, Diagn Pathol. 20 juin, vol.7, p.42, 2012.

B. Acs, V. Pelekanou, Y. Bai, S. Martinez-morilla, M. Toki et al., Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study, Lab Investig J Tech Methods Pathol. janv, vol.99, issue.1, pp.107-124, 2019.

D. L. Rimm, S. Leung, L. M. Mcshane, Y. Bai, A. L. Bane et al., An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer, Mod Pathol Off J U S Can Acad Pathol Inc. janv, vol.32, issue.1, pp.59-69, 2019.

V. M. Neumeister, V. Anagnostou, S. Siddiqui, A. M. England, and E. R. Zarrella,

M. Vassilakopoulou, Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues, J Natl Cancer Inst. 5 déc, vol.104, issue.23, pp.1815-1839, 2012.

A. C. Wolff, M. Hammond, D. G. Hicks, M. Dowsett, L. M. Mcshane et al., Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.31, pp.3997-4013, 2013.

X. Qian, H. Y. Wen, Y. Yang, F. Gu, X. Guo et al., Assessment of dualprobe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines, Breast Cancer Res Treat. août, vol.159, issue.1, pp.31-40, 2016.

N. C. Wu, W. Wong, K. E. Ho, V. C. Chu, A. Rizo et al., Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform, Breast Cancer Res Treat, vol.172, issue.2, pp.327-365, 2018.

J. Lehmann-che, A. -. Bouhidel, F. Turpin, E. Antoine, M. Soliman et al., Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches, Br J Cancer. 24 mai, vol.104, issue.11, pp.1739-1785, 2011.

S. Gupta, N. R. Mani, D. E. Carvajal-hausdorf, V. Bossuyt, K. Ho et al.,

, Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer, Lab Investig J Tech Methods Pathol. 1 juin, 2018.

V. Kotoula, K. T. Kalogeras, G. Kouvatseas, D. Televantou, R. Kronenwett et al., Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research, Virchows Arch Int J Pathol. févr, vol.462, issue.2, pp.141-54, 2013.

Y. K?l?ç, A. Ç. Çelebiler, and M. Sak?zl?, Selecting housekeeping genes as references for the normalization of quantitative PCR data in breast cancer, Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. févr, vol.16, issue.2, pp.184-90, 2014.

S. A. Bustin, V. Benes, T. Nolan, and M. W. Pfaffl, Quantitative real-time RT-PCR--a perspective, J Mol Endocrinol. juin, vol.34, issue.3, pp.597-601, 2005.

S. O. Bachmann, M. Sledziowska, E. Cross, S. Kalbassi, S. Waldron et al.,

, Behavioral training rescues motor deficits in Cyfip1 haploinsufficiency mouse model of autism spectrum disorders, Transl Psychiatry. 21 janv, vol.9, issue.1, p.29, 2019.

X. Shi, X. Chen, W. C. Li, L. J. Mo, Z. Y. Lin et al., Low expression of Cyfip1 may be a potential biomarker in nasopharyngeal carcinoma, Neoplasma, vol.65, issue.2, pp.292-297, 2018.

M. G. Hanna, I. J. Bleiweiss, A. Nayak, S. Jaffer, T. R. Wilson et al., Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765), Breast Cancer Res Treat. févr, vol.148, issue.2, pp.109-126, 2011.

Z. Varga, A. Lebeau, H. Bu, A. Hartmann, F. Penault-llorca et al., An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®, Breast Cancer Res BCR. 11 mai, vol.19, issue.1, p.55, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01675147

X. Du, X. Li, L. Li, Y. Xu, and Y. Feng, The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis, Breast Cancer Res Treat. févr, vol.138, issue.1, pp.59-67, 2013.

C. P. Akuoko, E. Armah, T. Sarpong, D. Y. Quansah, I. Amankwaa et al., Barriers to early presentation and diagnosis of breast cancer among African women living in sub-Saharan Africa, South Afr Med J Suid-Afr Tydskr Vir Geneeskd. mai, vol.12, issue.2, pp.377-386, 2014.

B. A. Pinsky, M. K. Sahoo, J. Sandlund, M. Kleman, M. Kulkarni et al.,

M. J. Broadhurst, J. D. Kelly, A. Miller, A. Semper, D. Bailey et al., ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study, Lancet Lond Engl. 29 août, vol.10, issue.12, pp.867-74, 2015.

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur sont affaiblies, vulnérables ou menacées dans leur intégrité? ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité? des circonstances pour forcer les consciences

, Admise dans l'intimité? des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dép pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'a? leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, En présence des Maitres de cette FACULTE et de mes chers CONDISCIPLES, je promets et je jure d'être fidèle aux lois de l'Honneur et de la Probité? dans l'exercice de la Médecine

, Je donnerai mes soins gratuits à l'indigent et je n'exigerai jamais un salaire au-dessus de mon travail

, Respectueuse et reconnaissante envers mes MAI?TRES, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères

, Que les HOMMES m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couverte d'OPPROBRE et méprisée de mes confrères si j'y manque

B. Charlyne,